EGFR mutations are linked with good prognosis in lung cancer patients mainly attributed to the treatment of tyrosine kinase inhibitor (TKI) [12], but also seen in surgically resected non-small cell lung cancer (NSCLC) without receiving TKI [13]. Here, EGFR is linked to non-small cell lung carcinoma.